Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
$0.66
$0.74
$0.55
$4.56
$16.15MN/AN/A574,675 shs
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
$4.54
$11.07
$35.71
$11.99M1.183,849 shs3,700 shs
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$5.54
$5.55
$2.61
$5.65
$290.24M1.25376,318 shsN/A
CohBar, Inc. stock logo
CWBR
CohBar
$0.41
$0.41
$0.00
$1.01
$1.19M1.394,364 shsN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$3.26
0.0%
$3.66
$2.85
$29.44
$5.17M0.0388,525 shs4,783 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
0.00%0.00%0.00%0.00%0.00%
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
0.00%0.00%0.00%0.00%0.00%
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00%0.00%0.00%0.00%+0.36%
CohBar, Inc. stock logo
CWBR
CohBar
0.00%0.00%0.00%0.00%-18.00%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00%-8.69%-14.46%+4.12%-62.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
0.00
N/AN/AN/A
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
0.00
N/AN/AN/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00
N/AN/AN/A
CohBar, Inc. stock logo
CWBR
CohBar
0.00
N/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/AN/AN/AN/A
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
$140K0.00N/AN/A($16.07) per share0.00
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$99.68M2.91N/AN/A$0.88 per share6.30
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/AN/A$5.27 per shareN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/A($20.31) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
-$26.24MN/A0.00N/AN/AN/AN/AN/A
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
-$14.80M-$13.03N/AN/AN/A-10,424.65%N/A-120.90%N/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/A
CohBar, Inc. stock logo
CWBR
CohBar
-$12.18MN/A0.00N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$13.42MN/A0.00N/AN/AN/AN/A8/13/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/AN/AN/A
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/AN/AN/AN/AN/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
N/AN/AN/AN/AN/A
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/A
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/A
0.13
0.36
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
1.80
2.79
2.62
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/A
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
12.50%
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
99.83%
CohBar, Inc. stock logo
CWBR
CohBar
2.47%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
3.18%

Insider Ownership

CompanyInsider Ownership
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
20.20%
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
6.50%
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
31.40%
CohBar, Inc. stock logo
CWBR
CohBar
6.51%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
3024.46 million19.52 millionNot Optionable
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
51.08 million1.01 millionNot Optionable
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
15052.39 million35.94 millionOptionable
CohBar, Inc. stock logo
CWBR
CohBar
102.91 millionN/ANot Optionable
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
501.64 million1.61 millionNot Optionable

Recent News About These Companies

Qualigen Therapeutics, Inc. (QLGN) - Yahoo Finance
Qualigen Therapeutics to participate in next funding round for NanoSynex
Qualigen to participate in next funding round for NanoSynex
Qualigen Therapeutics secures $4.5 million in funding

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Acer Therapeutics stock logo

Acer Therapeutics NASDAQ:ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

AgeX Therapeutics stock logo

AgeX Therapeutics NYSE:AGE

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

Alimera Sciences stock logo

Alimera Sciences NASDAQ:ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

CohBar stock logo

CohBar NASDAQ:CWBR

$0.41 0.00 (0.00%)
As of 01/23/2025

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

Qualigen Therapeutics stock logo

Qualigen Therapeutics NASDAQ:QLGN

$3.26 0.00 (-0.03%)
Closing price 07/3/2025 03:10 PM Eastern
Extended Trading
$3.26 0.00 (-0.09%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.